

Daniele Masarone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5641298/publications.pdf>

Version: 2024-02-01

65
papers

911
citations

516215

16
h-index

525886

27
g-index

67
all docs

67
docs citations

67
times ranked

1440
citing authors

#	ARTICLE	IF	CITATIONS
1	Hemodynamic Effects of Levosimendan in Outpatients With Advanced Heart Failure: An Echocardiographic Pilot Study. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 79, e36-e40.	0.8	6
2	Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study. <i>International Journal of Cardiology</i> , 2022, 350, 62-68.	0.8	13
3	Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan. <i>ESC Heart Failure</i> , 2022, 9, 1107-1117.	1.4	12
4	Use of Cardiac Contractility Modulation as Bridge to Transplant in an Obese Patient With Advanced Heart Failure: A Case Report. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 833143.	1.1	1
5	Advanced heart failure: state of the art and future directions. <i>Reviews in Cardiovascular Medicine</i> , 2022, 23, 048.	0.5	5
6	Last before-death alert remote monitoring transmission in patients with heart failure with reduced ejection fraction. <i>Kardiologia Polska</i> , 2022, 80, 254-255.	0.3	0
7	Add-on Therapy With Sacubitril/Valsartan and Clinical Outcomes in CRT-D Nonresponder Patients. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 79, 472-478.	0.8	4
8	Insulin-like growth factor-1 (IGF-1) as predictor of cardiovascular mortality in heart failure patients: data from the T.O.S.CA. registry. <i>Internal and Emergency Medicine</i> , 2022, 17, 1651-1660.	1.0	4
9	Angiotensin-converting enzyme inhibitor therapy after heart transplant: from molecular basis to clinical effects. <i>Clinical Transplantation</i> , 2022, , e14696.	0.8	1
10	Progressive right ventricular dysfunction and exercise impairment in patients with heart failure and diabetes mellitus: insights from the T.O.S.CA. Registry. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	6
11	Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF. <i>ESC Heart Failure</i> , 2022, 9, 2909-2917.	1.4	10
12	Exercise-based rehabilitation strategies in heart transplant recipients: Focus on high-intensity interval training. <i>Clinical Transplantation</i> , 2021, 35, e14143.	0.8	4
13	Use of sacubitril/valsartan as "bridge to transplant" in patients with end-stage hypertrophic cardiomyopathy. <i>Future Cardiology</i> , 2021, 17, 89-94.	0.5	1
14	Clinical relevance of transient worsening renal function after initiation of sacubitril/valsartan. <i>Current Medical Research and Opinion</i> , 2021, 37, 9-12.	0.9	5
15	Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: the T.O.S.CA. Registry. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1691-1700.	0.8	26
16	Left Ventricular Assist Device Implantation in a Thrombosed Apical Aneurysm. <i>Clinics and Practice</i> , 2021, 11, 430-434.	0.6	2
17	The Use of β -Blockers in Heart Failure with Reduced Ejection Fraction. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 101.	0.8	14
18	Nonresponse to Acute Vasodilator Challenge and Prognosis in Heart Failure With Pulmonary Hypertension. <i>Journal of Cardiac Failure</i> , 2021, 27, 869-876.	0.7	4

#	ARTICLE	IF	CITATIONS
19	Advanced Heart Failure: From Pathophysiology to Clinical Management. Heart Failure Clinics, 2021, 17, i.	1.0	0
20	Management of Advanced Heart Failure: The Science of Uncertainty and the Art of Probability. Heart Failure Clinics, 2021, 17, xv-xvi.	1.0	0
21	Echocardiography in Advanced Heart Failure for Diagnosis, Management, and Prognosis. Heart Failure Clinics, 2021, 17, 547-560.	1.0	4
22	Inotropes in Patients with Advanced Heart Failure. Heart Failure Clinics, 2021, 17, 587-598.	1.0	14
23	Repeated infusion of levosimendan in outpatients with advanced heart failure: to cure sometimes, to relieve often, and to comfort always. Journal of Cardiovascular Medicine, 2021, 22, 150.	0.6	1
24	Use of disease-modifying drugs in diabetic patients with heart failure with reduced ejection fraction. Heart Failure Reviews, 2021, , 1.	1.7	3
25	Use of Cardiac Contractility Modulation in an Older Patient with Non-Ischemic Dilated Cardiomyopathy: A Case Report. Clinics and Practice, 2021, 11, 835-840.	0.6	2
26	The Role of Echocardiography in the Management of Heart Transplant Recipients. Diagnostics, 2021, 11, 2338.	1.3	6
27	Effect of cardiac contractility modulation therapy on myocardial work in patients with heart failure with reduced ejection fraction. European Heart Journal Supplements, 2021, 23, .	0.0	0
28	Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2020, 299, 186-191.	0.8	58
29	Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. European Journal of Internal Medicine, 2020, 71, 23-31.	1.0	29
30	Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism. European Journal of Preventive Cardiology, 2020, 27, 1906-1908.	0.8	16
31	Beta-blocker therapy in heart transplant recipients: A review. Clinical Transplantation, 2020, 34, e14081.	0.8	1
32	Effects of Sacubitril/Valsartan on the Right Ventricular Arterial Coupling in Patients with Heart Failure with Reduced Ejection Fraction. Journal of Clinical Medicine, 2020, 9, 3159.	1.0	17
33	Myocarditis in Children. , 2020, , 243-260.		2
34	Efficacy and safety of repeated infusion of levosimendan in outpatients with advanced heart failure: a real-world experience. Journal of Cardiovascular Medicine, 2020, 21, 919-921.	0.6	11
35	Berlin Heart EXCOR® pediatric ventricular assist device in a patient with Sotos syndrome: a case report. Journal of Medical Case Reports, 2019, 13, 286.	0.4	1
36	Beta Blockers Up-Titration in Patients with Heart Failure Reduced Ejection Fraction and Cardiac Resynchronization Therapy, a Single Center Study. Medical Sciences (Basel, Switzerland), 2019, 7, 71.	1.3	1

#	ARTICLE	IF	CITATIONS
37	Left atrial volume during stress is associated with increased risk of arrhythmias in patients with hypertrophic cardiomyopathy. <i>Journal of Cardiovascular Echography</i> , 2019, 29, 1.	0.1	9
38	Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.C.A. Registry. <i>Internal and Emergency Medicine</i> , 2018, 13, 661-671.	1.0	41
39	Epidemiology and Clinical Aspects of Genetic Cardiomyopathies. <i>Heart Failure Clinics</i> , 2018, 14, 119-128.	1.0	32
40	Are microRNA useful to predict prognosis in acute heart failure?. <i>Journal of Laboratory and Precision Medicine</i> , 2018, 3, 14-14.	1.1	1
41	Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3726.	1.8	63
42	Risk Stratification of Sudden Cardiac Death in Patients with Heart Failure: An update. <i>Journal of Clinical Medicine</i> , 2018, 7, 436.	1.0	27
43	A therapeutic genome editing primer for cardiologist. <i>Neurology International</i> , 2018, 8, .	0.2	1
44	Diagnostic clues for the diagnosis of nonsarcomeric hypertrophic cardiomyopathy (Phenocopies): Amyloidosis, fabry disease, and mitochondrial disease. <i>Journal of Cardiovascular Echography</i> , 2018, 28, 120.	0.1	10
45	Clinical and genetic characterization of patients with hypertrophic cardiomyopathy and right atrial enlargement. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 249-254.	0.6	9
46	Mitochondrial disease and the heart. <i>Heart</i> , 2017, 103, 390-398.	1.2	28
47	Pediatric Heart Failure: A Practical Guide to Diagnosis and Management. <i>Pediatrics and Neonatology</i> , 2017, 58, 303-312.	0.3	69
48	Management of pregnancy in cardiomyopathies and heart failure. <i>Future Cardiology</i> , 2017, 13, 81-96.	0.5	5
49	Severe hypertrophic cardiomyopathy in a patient with atypical Anderson-Fabry disease. <i>Future Cardiology</i> , 2017, 13, 521-527.	0.5	2
50	Exercise speckle-tracking strain imaging demonstrates impaired right ventricular contractile reserve in hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2017, 227, 209-216.	0.8	24
51	Management of Bradyarrhythmias in Heart Failure: A Tailored Approach. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1067, 255-269.	0.8	2
52	Management of Arrhythmias in Heart Failure. <i>Journal of Cardiovascular Development and Disease</i> , 2017, 4, 3.	0.8	47
53	Growth Hormone Deficiency Is Associated with Worse Cardiac Function, Physical Performance, and Outcome in Chronic Heart Failure: Insights from the T.O.S.C.A. GHD Study. <i>PLoS ONE</i> , 2017, 12, e0170058.	1.1	59
54	Pathogenesis of Takotsubo Syndrome. <i>Neurology International</i> , 2016, 6, 5973.	0.2	0

#	ARTICLE	IF	CITATIONS
55	Genetics of Takotsubo Syndrome. <i>Heart Failure Clinics</i> , 2016, 12, 499-506.	1.0	19
56	Renal Function and Peak Exercise Oxygen Consumption in Chronic Heart Failure With Reduced Left Ventricular Ejection Fraction. <i>Circulation Journal</i> , 2015, 79, 583-591.	0.7	29
57	Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group. <i>European Journal of Internal Medicine</i> , 2015, 26, 515-520.	1.0	16
58	Right Ventricular Cardiomyopathies: A Multidisciplinary Approach to Diagnosis. <i>Echocardiography</i> , 2015, 32, S75-94.	0.3	13
59	Cardiac resynchronization therapy in cardiomyopathies. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 92-99.	0.6	2
60	Effect of cardiac resynchronization therapy on cardiotrophin-1 circulating levels in patients with heart failure. <i>Internal and Emergency Medicine</i> , 2014, 9, 43-50.	1.0	9
61	Takotsubo Cardiomyopathy. <i>Heart Failure Clinics</i> , 2013, 9, 207-216.	1.0	25
62	Natriuretic peptides: molecular biology, pathophysiology and clinical implications for the cardiologist. <i>Future Cardiology</i> , 2013, 9, 519-534.	0.5	13
63	Mitochondrial diseases and the heart: an overview of molecular basis, diagnosis, treatment and clinical course. <i>Future Cardiology</i> , 2012, 8, 71-88.	0.5	54
64	Right ventricular hypertrabeculation associated with double-outlet left ventricle: exaggeration of a normal pattern or right ventricular cardiomyopathy?. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 193-195.	0.6	5
65	Cardiotrophin-1 and TNF- α circulating levels at rest and during cardiopulmonary exercise test in athletes and healthy individuals. <i>Cytokine</i> , 2010, 50, 245-247.	1.4	13